Merck Annual Report 2000 Merck Annual Report 2000 [Contents] 2 of 18
[Previous][Contents][Next]
[Products] [Financial Highlights] [Letter] [Innovation] [Access] [People] [Financials] [Management] [Corporate Info]
PROFILE

Merck Products* at a Glance – Our Products Provide a Powerful Platform for Growth

Name Generic Name  
Cardiovascular
Aggrastat® tirofiban hydrochloride
  • unstable angina
  • non-Q-wave myocardial infarction
Cozaar® losartan potassium
  • high blood pressure
Hyzaar® losartan potassium and hydrochlorothiazide
  • high blood pressure
Zocor® simvastatin
  • elevated cholesterol
  • associated total/coronary mortality1
  • raise HDL cholesterol
  • reduce triglycerides
  • reduce stroke risk1
  ezetimibe, Schering-Plough’s investigational cholesterol absorption inhibitor, with Zocor2,3
  • lower elevated cholesterol
Endocrinology
Fosamax® alendronate sodium
  • treatment and prevention of postmenopausal osteoporosis
  • reduced osteoporotic fracture risk
  • treatment of male osteoporosis to increase bone mass
  • treatment of glucocorticoid-induced osteoporosis
  • Paget’s disease of the bone
Propecia®  finasteride
  • treatment of male pattern hair loss
Proscar®  finasteride
  • treatment of symptomatic benign prostate enlargement
Gastrointestinal
Pepcid AC®4 famotidine
  • heartburn
Infection
Cancidas® caspofungin acetate
  • treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies
Crixivan® indinavir sulfate
  • HIV infection
Stocrin®5 efavirenz
  • HIV infection
Invanz®6 ertapenem sodium
  • initial empiric treatment of community-acquired and mixed infections, such as intra-abdominal infections
Inflammation
Vioxx® rofecoxib
  • osteoarthritis
  • acute pain
MK-6633 etoricoxib
  • osteoarthritis
  • acute pain
  • rheumatoid arthritis
Neurological
Maxalt® rizatriptan benzoate
  • acute migraine
MK-8693  
  • emesis due to chemotherapy
Substance P
Antagonist3
 
  • depression and anxiety
Ophthalmic
Cosopt® dorzolamide hydrochloride and timolol maleate
  • lower intraocular pressure
Trusopt® dorzolamide hydrochloride
  • lower intraocular pressure
Timoptic-XE® timolol maleate ophthalmic gel forming solution
  • lower intraocular pressure
Respiratory
Singulair® montelukast sodium
  • chronic asthma–adults and in children as young as age 2
  fixed-combination tablet2,3 containing Claritin® (loratadine) and Singulair
  • allergic rhinitis
Vaccines
Comvax® Haemophilus b conjugate and hepatitis B (recombinant) vaccine
  • Haemophilus influenzae type b disease and hepatitis B disease
HIV/AIDS3  
  • HIV/AIDS
Herpes zoster3  
  • herpes zoster (shingles) in adults
Human papillomavirus3  
  • HPV infections and prevention of cervical cancer
Rotavirus3  
  • Rotaviral infections
Vaqta® inactivated hepatitis A vaccine
  • Hepatitis A
Varivax® varicella virus vaccine live [Oka/Merck strain]
  • Chickenpox

* This list excludes a number of older Company products introduced before 1990
1 In patients with coronary heart disease and elevated cholesterol
2 Under development by Merck and Schering-Plough Corporation joint ventures
3 Products in development
4 Marketed by the Johnson & Johnson • Merck Consumer Pharmaceuticals Co.
5 Efavirenz is marketed by DuPont Pharmaceuticals Company as Sustiva in the U.S.,
   Canada and certain European countries and by Merck in the rest of the world as Stocrin
6 Products under U.S. Food and Drug Administration review for marketing approval

[Contents] 2 of 18
[Previous][Contents][Next]
[Products] [Financial Highlights] [Letter] [Innovation] [Access] [People] [Financials] [Management] [Corporate Info]
Merck Annual Report 2000 Merck Annual Report 2000
Copyright © 1995-2001 Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.